Last $5.97 USD
Change Today +0.05 / 0.84%
Volume 5.9M
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Open
$5.91
Previous Close
$5.92
Day High
$6.08
Day Low
$5.83
52 Week High
02/28/14 - $6.95
52 Week Low
04/15/14 - $3.34
Market Cap
1.4B
Average Volume 10 Days
4.3M
EPS TTM
$-0.30
Shares Outstanding
238.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants. The company’s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology that includes virus-like particles vaccines and protein nanoparticle vaccines. Its vaccine candidates target seasonal influenza, pandemic influenza, and respiratory syncytial virus. The company also develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

213 Employees
Last Reported Date: 03/12/14
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $448.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $156.3K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $371.9K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $284.5K
Compensation as of Fiscal Year 2013.

novavax inc (NVAX) Key Developments

Novavax, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:00 AM

Novavax, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Stanley C. Erck, Chief Executive Officer, President, Director and Member of Finance Committee.

U.S. Food and Drug Administration Grants Fast Track Designation to Novavax' RSV F-Protein Nanoparticle Vaccine for Protection of Infants

Novavax, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for protection of infants through maternal immunization. Maternal immunization represents a strategy to protect newborn infants through the transfer of maternal antibodies through active transport mechanisms in the placenta, thus providing the infant the benefit of the mother's full repertoire of antibodies at the time of birth. The biology of maternal immunization is well-understood and accepted, and maternal immunization is a recommended practice for several marketed vaccines such as tetanus, pertussis and seasonal influenza. RSV is a major respiratory pathogen with a significant burden of disease in the very young and in the elderly. In healthy adults, RSV infections are generally mild to moderate in severity, but are typically more severe in infants and young children as well as adults over the age of 60. Globally, RSV is a common cause of childhood respiratory infection, with a disease burden of 64 million cases and approximately 160,000 deaths annually. Severe RSV disease results in 3.4 million hospital admissions per year globally and disproportionately affects infants below six months of age. In infants, toddlers and young pre-school and school-age children, RSV infections result in the need for frequent medical care, including ER and office visits and are associated with increased recurrent wheezing that can persist for years. It is also estimated that between 11,000 to 17,000 elderly and high risk adults die of RSV infection or its complications annually in the U.S., and up to 180,000 are hospitalized for serious respiratory symptoms. Currently, there is no approved RSV vaccine available for any of these populations.

Novavax, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 02:20 PM

Novavax, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 02:20 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: Stanley C. Erck, Chief Executive Officer, President, Director and Member of Finance Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $5.97 USD +0.05

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $15.34 USD -0.18
Inovio Pharmaceuticals Inc $9.48 USD +0.47
Peregrine Pharmaceuticals Inc $1.42 USD -0.04
Progenics Pharmaceuticals Inc $7.25 USD -0.095
ZIOPHARM Oncology Inc $4.80 USD +0.53
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.5x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.